The Week in Review #46
The Quarterly Financial Results
The quarterly financial results that analysts and investors relied on for years to evaluate biotech firms, including development stage firms, seem to change. Investors have finally realized that development-stage firms have no marketed drugs and no revenues, hence, no incomes and should be evaluated based on the clinical trial results of their pipeline products. They saw how the stocks of development-stage biotech firms’ stock prices that have been downgraded based on their financial results have surged based on their products’ efficacy and safety as demonstrated in the clinical trial . . .
This content is for paid subscribers.
Prohost Letters November 4, 2019